$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000162828017007796 Filed on August 02, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$18.00K	$18.00K	$483.0K
YoY Change	-91.18%	-96.27%	-87.4%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.740M	$7.060M	$3.660M
YoY Change	-43.39%	92.9%	-37.01%
% of Gross Profit
Research & Development	$12.70M	$14.28M	$18.01M
YoY Change	-12.76%	-20.71%	-6.22%
% of Gross Profit
Depreciation & Amortization	$580.0K	$660.0K	$510.0K
YoY Change	-12.12%	29.41%	24.39%
% of Gross Profit
Operating Expenses	$15.43M	$21.34M	$21.67M
YoY Change	-20.43%	-1.55%	-13.37%
Operating Profit	-$15.42M	-$21.32M	-$21.19M
YoY Change	-19.68%	0.61%	0.03%
Interest Expense	$580.0K	$603.0K	$90.00K
YoY Change	3.57%	570.0%	1185.71%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$15.84M	-$21.74M	-$21.10M
YoY Change	-18.86%	3.02%	0.29%
Income Tax	-$7.000K	-$128.0K	-$8.000K
% Of Pretax Income
Net Earnings	-$15.83M	-$21.61M	-$21.09M
YoY Change	-18.91%	2.46%	0.26%
Net Earnings / Revenue	-87933.33%	-120044.44%	-4366.46%
Basic Earnings Per Share			-$0.40
Diluted Earnings Per Share	-$2.108M	-$4.878M	-$4.793M
COMMON SHARES
Basic Shares Outstanding	103.8M shares	53.18M shares	52.78M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$71.40M	$40.10M	$107.5M
YoY Change	-22.05%	-62.7%	-22.88%
Cash & Equivalents	$20.22M	$12.54M	$27.04M
Short-Term Investments	$51.10M	$27.50M	$80.50M
Other Short-Term Assets	$1.752M	$3.018M	$522.0K
YoY Change	556.18%	478.16%	-87.27%
Inventory
Prepaid Expenses	$5.912M	$6.149M	$7.565M
Receivables	$500.0K	$700.0K	$100.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$79.57M	$49.94M	$116.2M
YoY Change	-22.62%	-57.03%	-19.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.17M	$10.75M	$12.32M
YoY Change	-15.53%	-12.73%	272.27%
Goodwill
YoY Change
Intangibles	$802.0K	$823.0K	$1.062M
YoY Change	-23.69%	-22.5%	-0.93%
Long-Term Investments
YoY Change
Other Assets	$307.0K	$340.0K	$310.0K
YoY Change	-10.5%	9.68%	-82.72%
Total Long-Term Assets	$11.28M	$11.92M	$13.69M
YoY Change	-16.04%	-12.98%	121.73%
TOTAL ASSETS
Total Short-Term Assets	$79.57M	$49.94M	$116.2M
Total Long-Term Assets	$11.28M	$11.92M	$13.69M
Total Assets	$90.85M	$61.86M	$129.9M
YoY Change	-21.86%	-52.39%	-13.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.229M	$4.901M	$3.504M
YoY Change	-8.65%	39.87%	45.58%
Accrued Expenses	$4.770M	$4.717M	$5.472M
YoY Change	-5.84%	-13.8%	-19.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.76M	$11.12M	$11.10M
YoY Change	-10.6%	0.23%	-23.72%
LONG-TERM LIABILITIES
Long-Term Debt	$19.80M	$19.80M	$19.80M
YoY Change	0.0%	0.0%
Other Long-Term Liabilities	$351.0K	$283.0K	$8.570M
YoY Change	-95.93%	-96.7%	965.92%
Total Long-Term Liabilities	$351.0K	$283.0K	$8.570M
YoY Change	-95.93%	-96.7%	965.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.76M	$11.12M	$11.10M
Total Long-Term Liabilities	$351.0K	$283.0K	$8.570M
Total Liabilities	$42.27M	$41.87M	$41.48M
YoY Change	-3.02%	0.92%	135.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$331.4M	-$315.6M	-$233.8M
YoY Change	30.82%	34.97%	36.5%
Common Stock	$380.1M	$335.7M	$322.3M
YoY Change	16.55%	4.13%	6.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$48.58M	$20.00M	$88.45M
YoY Change
Total Liabilities & Shareholders Equity	$90.85M	$61.86M	$129.9M
YoY Change	-21.86%	-52.39%	-13.53%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$15.83M	-$21.61M	-$21.09M
YoY Change	-18.91%	2.46%	0.26%
Depreciation, Depletion And Amortization	$580.0K	$660.0K	$510.0K
YoY Change	-12.12%	29.41%	24.39%
Cash From Operating Activities	-$11.66M	-$17.33M	-$17.35M
YoY Change	-24.77%	-0.12%	77.58%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	$20.00K	$130.0K
YoY Change	-79.17%	-84.62%	-176.47%
Acquisitions
YoY Change
Other Investing Activities	-$23.70M	$14.96M	$5.170M
YoY Change	-795.01%	189.36%	-50.76%
Cash From Investing Activities	-$23.80M	$14.98M	$5.300M
YoY Change	-909.52%	182.64%	-48.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	43.15M	0.000	19.83M
YoY Change	18660.87%	-100.0%	2055.43%
NET CHANGE
Cash From Operating Activities	-11.66M	-17.33M	-17.35M
Cash From Investing Activities	-23.80M	14.98M	5.300M
Cash From Financing Activities	43.15M	0.000	19.83M
Net Change In Cash	7.690M	-2.350M	7.780M
YoY Change	-162.37%	-130.21%	425.68%
FREE CASH FLOW
Cash From Operating Activities	-$11.66M	-$17.33M	-$17.35M
Capital Expenditures	-$100.0K	$20.00K	$130.0K
Free Cash Flow	-$11.56M	-$17.35M	-$17.48M
YoY Change	-23.04%	-0.74%	82.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	REGULUS THERAPEUTICS INC.
	dei	Trading Symbol TradingSymbol	RGLS
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	83000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001505512
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	103785730	shares
	rgls	Noncashor Part Noncash Intangible Assets Accrued Cost Not Yet Paid NoncashorPartNoncashIntangibleAssetsAccruedCostNotYetPaid	7000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5247000	USD
	rgls	Restricted Cash Tenant Improvement Allowance RestrictedCashTenantImprovementAllowance	-794000	USD
	rgls	Noncashor Part Noncash Intangible Assets Accrued Cost Not Yet Paid NoncashorPartNoncashIntangibleAssetsAccruedCostNotYetPaid	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-972000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-36000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-529000	USD
	rgls	Restricted Cash Tenant Improvement Allowance RestrictedCashTenantImprovementAllowance	0	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-885000	USD
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q2	dei	Entity Number Of Employees EntityNumberOfEmployees	65	employee
	rgls	Short Term Investment Maturity Weighted Average ShortTermInvestmentMaturityWeightedAverage	P1Y
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1970000	USD
CY2017Q2	rgls	Cashand Cash Equivalentsand Marketable Securities CashandCashEquivalentsandMarketableSecurities	40100000	USD
CY2017Q1	rgls	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount	7400000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	61236000	USD
CY2017Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	27559000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	221000	USD
CY2016Q4	rgls	Prepaid Expenses Reserve PrepaidExpensesReserve	600000	USD
CY2017Q2	rgls	Prepaid Expenses Reserve PrepaidExpensesReserve	600000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2238000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5986000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2865000	USD
CY2017Q2	rgls	Workforce Reduction Commitment Rate WorkforceReductionCommitmentRate	0.30
CY2016Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1657000	USD
CY2017Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	690000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5840000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4901000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-359000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-181000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5577000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4717000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-123000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-88000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	329496000	USD
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	335612000	USD
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3055143	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2639630	shares
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2140111	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2869643	shares
CY2016Q4	us-gaap	Assets Assets	100661000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	110000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15960000	USD
CY2017Q2	us-gaap	Assets Assets	61860000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	87474000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	49944000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	61170000	USD
CY2017Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	27549000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12000	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	78000	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10000	USD
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27040000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14941000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12538000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11080000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2403000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13603716	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52924805	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53182330	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52924805	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53182330	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	53000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	53000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21081000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42246000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21598000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41593000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	38000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8840000	USD
CY2017Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8672000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72000	USD
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1993000	USD
CY2017Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1957000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	928000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1357000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.80
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.78
CY2017Q2	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	1300000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2318000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1433000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3664000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8767000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7057000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11016000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21098000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42309000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21736000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-41761000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-13000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-128000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-132000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-9878000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-967000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	787000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-907000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1063000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-814000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-262000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-187000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1106000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2834000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	597000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1015000	USD
CY2017Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	823000	USD
CY2016Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	180000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	372000	USD
CY2017Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	184000	USD
	us-gaap	Interest And Other Income InterestAndOtherIncome	398000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	90000	USD
	us-gaap	Interest Expense InterestExpense	114000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	603000	USD
	us-gaap	Interest Expense InterestExpense	1149000	USD
	us-gaap	Interest Paid InterestPaid	54000	USD
	us-gaap	Interest Paid InterestPaid	946000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	44586000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	41865000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	100661000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61860000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13807000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11123000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	19802000	USD
CY2017Q2	us-gaap	Long Term Debt LongTermDebt	19830000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20364000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	268000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16991000	USD
CY2017Q2	us-gaap	Other Assets Current OtherAssetsCurrent	3018000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	342000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	340000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	33336000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26275000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36007000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-21090000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-42296000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-21608000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-41629000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	21671000	USD
	us-gaap	Operating Expenses OperatingExpenses	43539000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	21335000	USD
	us-gaap	Operating Expenses OperatingExpenses	41046000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-21188000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-42567000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-21317000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-41010000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4154000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	50000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	10000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	36000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	144000	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	283000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	45000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	190000	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	6545000	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	34000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	16000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	266000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	124000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	30231000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	4453000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5552000	USD
CY2017Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6149000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	363000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	265000	USD
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	19819000	USD
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	0	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	47522000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	37929000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	265000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11830000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10753000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10819000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10819036	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.70
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18007000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34772000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14278000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30030000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1300000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-273351000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-315582000	USD
CY2016Q2	us-gaap	Revenues Revenues	483000	USD
	us-gaap	Revenues Revenues	972000	USD
CY2017Q2	us-gaap	Revenues Revenues	18000	USD
	us-gaap	Revenues Revenues	36000	USD
CY2017Q2	us-gaap	Severance Costs1 SeveranceCosts1	3200000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5986000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5247000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2359000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.86
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	4255000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8931000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.82
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.38
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.44
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	61170000	USD
CY2017Q2	us-gaap	Short Term Investments ShortTermInvestments	27549000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8000	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	56075000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	19995000	USD
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52782643	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52746657	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53182330	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53086887	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-007796-index-headers.html	Edgar Link	pending
0001628280-17-007796-index.html	Edgar Link	pending
0001628280-17-007796.txt	Edgar Link	pending
0001628280-17-007796-xbrl.zip	Edgar Link	pending
ex-101xdeegmarkemploymenta.htm	Edgar Link	pending
ex-102xhaganjaybasesalarya.htm	Edgar Link	pending
ex-103xgrintpaulseparation.htm	Edgar Link	pending
ex-311x20170630.htm	Edgar Link	pending
ex-312x20170630.htm	Edgar Link	pending
ex-321x20170630.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
paulgrintseparationag_image1.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20170630.xml	Edgar Link	completed
rgls-20170630.xsd	Edgar Link	pending
rgls-20170630_cal.xml	Edgar Link	unprocessable
rgls-20170630_def.xml	Edgar Link	unprocessable
rgls-20170630_lab.xml	Edgar Link	unprocessable
rgls-20170630_pre.xml	Edgar Link	unprocessable
rgls20170630-10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2017 Q3 Form 10-Q Financial Statement

#000162828017007796 Filed on August 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2017 Q3 Form 10-Q Financial Statement

#000162828017007796 Filed on August 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls